Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

被引：0
|
作者：
Eberhardt, W. E. E. [1 ]
Johnson, B. E. [2 ]
Sun, Y. [3 ]
Germonpre, P. [4 ]
Saijo, N. [5 ]
Zhou, C. [6 ]
Wang, J. [7 ]
Tada, H. [8 ]
Kennedy, S. [9 ]
Herbst, R. S. [10 ]
机构：
[1] Univ Duisburg Essen, German Tumor Ctr, Essen, Germany
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Canc Hosp, Beijing, Peoples R China
[4] Univ Antwerp Hosp, Antwerp, Belgium
[5] Natl Canc Ctr Hosp E, Chiba, Japan
[6] Tongji Univ, Shanghai 200092, Peoples R China
[7] Beijing Inst Canc Res, Beijing, Peoples R China
[8] AstraZeneca, Med Sci, Wilmington, DE USA
[9] AstraZeneca, Biostat, Macclesfield, Cheshire, England
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71714-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：505 / 505
页数：1
相关论文
共 50 条
  • [21] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
    Boer, Katalin
    Lang, Istvan
    Llombart-Cussac, Antonio
    Andreasson, Inger
    Vivanco, Guillermo L.
    Sanders, Nick
    Pover, Gillian M.
    Murray, Elizabeth
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 681 - 687
  • [22] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
    Katalin Boér
    István Láng
    Antonio Llombart-Cussac
    Inger Andreasson
    Guillermo L. Vivanco
    Nick Sanders
    Gillian M. Pover
    Elizabeth Murray
    Investigational New Drugs, 2012, 30 : 681 - 687
  • [23] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo controlled, randomized phase II study.
    Boer, K.
    Lang, I
    Llombart-Cussac, A.
    Andreasson, I
    Vivanco, G. L.
    Sanders, N.
    Paver, G. M.
    Murray, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S274 - S274
  • [24] Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
    Smit, Egbert F.
    Garon, Edward B.
    Reck, Martin
    Cappuzzo, Federico
    Bidoli, Paolo
    Cohen, Roger B.
    Gao, Ling
    O'Brien, Lisa M.
    Lee, Pablo
    Zimmermann, Annamaria
    Ferry, David R.
    Melemed, Allen S.
    Perol, Maurice
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 77 - 86
  • [25] Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
    Syrios, John
    Nintos, Georgios
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (08) : 875 - 884
  • [26] Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    Takeda, K.
    Negoro, S.
    Tamura, T.
    Nishiwaki, Y.
    Kudoh, S.
    Yokota, S.
    Matsui, K.
    Semba, H.
    Nakagawa, K.
    Takada, Y.
    Ando, M.
    Shibata, T.
    Saijo, N.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 835 - 841
  • [27] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    L Paz-Ares
    H Ross
    M O'Brien
    A Riviere
    U Gatzemeier
    J Von Pawel
    E Kaukel
    L Freitag
    W Digel
    H Bischoff
    R García-Campelo
    N Iannotti
    P Reiterer
    I Bover
    J Prendiville
    A J Eisenfeld
    F B Oldham
    B Bandstra
    J W Singer
    P Bonomi
    British Journal of Cancer, 2008, 98 : 1608 - 1613
  • [28] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    Paz-Ares, L.
    Ross, H.
    O'Brien, M.
    Riviere, A.
    Gatzemeier, U.
    Von Pawel, J.
    Kaukel, E.
    Freitag, L.
    Digel, W.
    Bischoff, H.
    Garcia-Campelo, R.
    Iannotti, N.
    Reiterer, P.
    Bover, I.
    Prendiville, J.
    Eisenfeld, A. J.
    Oldham, F. B.
    Bandstra, B.
    Singer, J. W.
    Bonomi, P.
    BRITISH JOURNAL OF CANCER, 2008, 98 (10) : 1608 - 1613
  • [29] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [30] SECOND-LINE CHEMOTHERAPY (CT) WITH DOCETAXEL IN ELDERLY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS: A PHASE II STUDY
    Bernardini, I.
    Tibaldi, C.
    Chella, A.
    Galli, L.
    Russo, F.
    Toma, G.
    Tempestini, F.
    Santolicandro, A. M.
    Coltelli, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 34 - 34
12345